NUFORMIX PLC Logo

NUFORMIX PLC

NFX | IL

Overview

Corporate Details

ISIN(s):
GB00BYW79Y38
LEI:
2138003XG3H3I2J3BJ24
Country:
United Kingdom
Address:
6TH FLOOR, EC3V 0HR LONDON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Nuformix PLC is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology. The company's core strategy involves drug repurposing, utilizing its proprietary cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's lead development programs target conditions within oncology supportive care and fibrosis, aiming to create novel treatments from existing medicines.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for NUFORMIX PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-11 08:00
Legal Proceedings Report
US FDA ODD Application Submitted for NXP002
English 13.5 KB
2025-05-29 08:00
Regulatory News Service
Confirmation of European ODD for NXP002
English 13.6 KB
2025-05-28 11:28
Prospectus
Nuformix plc - Single prospectus
English 866.5 KB
2025-05-23 14:19
Prospectus
Prospectus
English 866.5 KB
2025-05-23 14:08
Report Publication Announcement
Publication of a Prospectus
English 13.3 KB
2025-02-28 13:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.3 KB
2025-02-14 15:18
Report Publication Announcement
Posting of Annual Report and Notice of AGM
English 8.4 KB
2025-01-30 08:00
Share Issue/Capital Change
£168,750 Placing
English 13.1 KB
2025-01-29 08:00
Annual / Quarterly Financial Statement
Annual Results for period ended 30 September 2024
English 414.7 KB
2025-01-28 08:00
Regulatory News Service
NXP002 ODD Application Submitted
English 11.4 KB
2025-01-13 08:00
Regulatory News Service
NXP002 Orphan Drug Designation Draft Application
English 9.6 KB
2024-11-29 18:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.1 KB
2024-11-05 15:25
Director's Dealing
Director/PDMR Dealings
English 39.9 KB
2024-11-04 11:17
Declaration of Voting Results & Voting Rights Announcements
Result of General Meeting
English 21.2 KB
2024-10-18 11:34
Prospectus
Nuformix plc - Single prospectus
English 1.6 MB

Automate Your Workflow. Get a real-time feed of all NUFORMIX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NUFORMIX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
VERICI DX PLC Logo
AI-powered diagnostic tests for the kidney transplant market, predicting organ rejection and injury.
United Kingdom VRCI
Vicore Pharma Holding Logo
Develops AT2 receptor drugs and a digital therapeutic for pulmonary fibrosis.
Sweden VICO
Vivoryon Therapeutics N.V. Logo
Develops small molecule therapies for severe age-related, inflammatory, and neurodegenerative diseases.
Germany VVY
R&D in renewable energy & manufacturing specialized tools for automotive & engineering.
Slovakia N/A
Xintela AB Logo
Develops stem cell therapies and targeted antibody treatments for cancer and osteoarthritis.
Sweden XINT
Xlife Sciences AG Logo
A life sciences incubator commercializing early-stage academic research for healthcare markets.
Switzerland XLS
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage therapeutics for autoimmune diseases.
Israel XTLB
Yoshi Innovation Spolka Akcyjna Logo
A tech fund incubating MedTech, biotech, and defense ventures with investment and IP protection.
Poland YOS
Zealand Pharma Logo
Develops innovative peptide medicines for metabolic and rare diseases.
Denmark ZEAL
Ziccum AB Logo
Licenses drying tech for thermostable vaccines & biologics, eliminating the cold chain.
Sweden ZICC